INS and metabolic dysfunction-associated steatohepatitis: CDN1163 treatment improved diet-induced steatohepatitis by restoring glucose tolerance and insulin sensitivity; reducing liver fibrosis, inflammation, oxidative stress and ER stress; normalizing hepatic pyruvate cycling; enhancing expression of mitochondrial respiratory genes; and elevating PUFA content in hepatocytes, which correlated to improvement of histological markers of MASH.